0 comments / 0 votes

Seventeen years ago this month, The Spectator quoted a consultant who predicted it would take decades for Hamilton to develop a bioscience technology sector, due to a lack of available land, and because companies weren’t knocking down the city’s door to be “anchor tenants.” But news out of McMaster Innovation Park suggests it’s anchors aweigh […]

0 comments / 0 votes

A research team at McMaster University has developed a self-cleaning surface that instantly repels viruses and bacteria – and could potentially prevent the transfer of superbugs (strains of bacteria resistant to most antibiotics). The transparent flexible film can be shrink-wrapped to fit onto door handles, railings, and other surfaces that act as magnets for bacteria. […]

0 comments / 0 votes
0 comments / 0 votes

Hamilton-based packaging manufacturer and supplier HT Productions Inc. will receive $3.9 million in federal funding that will create nearly 50 new skilled jobs in the city. Speaking to The Spectator on Monday, Economic Development Minister Mélanie Joly said the company will be able to expand its facility and “adopt a more customer-centric online system” with […]

0 comments / 0 votes
0 comments / 0 votes

Israel-based Isotopia Molecular Imaging and CPDC (Hamilton, Ontario) are pleased to announce that they have entered into an agreement for the production and distribution of no-carrier-added Lutetium-177 (n.c.a. Lu-177), a critical medical radioisotope used in the manufacturing of radiopharmaceuticals for treatment of many types of cancer, including neuroendocrine tumors and prostate cancer. The Centre for […]

0 comments / 0 votes
0 comments / 0 votes

Fusion Pharmaceuticals Inc., a Hamilton, Ontario-based clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced a collaboration with AstraZeneca to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer. The collaboration leverages Fusion’s Targeted Alpha Therapies (TATs) platform and expertise in radiopharmaceuticals with AstraZeneca’s leading portfolio […]

0 comments / 0 votes

Archives

> <
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec